Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

AI Briefing

• – Structure Therapeutics' GLP-1 receptor agonist Aleniglipron shows significant weight loss in Phase 2 trial.
• – 180 mg and 240 mg dosing regimens achieve 16.3% and 16.0% weight loss at 44 weeks.
• – Aleniglipron demonstrates highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs.